{"id":499825,"date":"2021-06-01T07:08:23","date_gmt":"2021-06-01T11:08:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/"},"modified":"2021-06-01T07:08:23","modified_gmt":"2021-06-01T11:08:23","slug":"myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/","title":{"rendered":"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SALT LAKE CITY, June  01, 2021  (GLOBE NEWSWIRE) &#8212; On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash.<\/p>\n<p>\n        <strong>About Myriad Genetics <\/strong><br \/>\n        <br \/>Myriad Genetics, is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where genetic testing can significantly improve patient care and lower healthcare costs. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Dga2y7jgrwkHhIeb64HzSRllrEqEQnsr1-DY3hzkVSc1jY9-DKMjXPwyyvb-EsBJ4yUFUCXZLoM24Lj6m2hhj60RjaAe1FkXE0KtGlj3ORvUdBRj2n8kZvrI2cQ3shlX-07O43LM2OyfYbB4x_6Hj0ndsdK6ht3klY-W0uzqFVdcUQvDc4WslpycoAirme422ilgPUxecqz6DuL5l4qo92QyemYdliWUbzDOLU6Ry8I=\" rel=\"nofollow noopener\" target=\"_blank\">www.myriad.com<\/a>.<br \/>Myriad, the Myriad logo, BART, BRAC<em>Analysis<\/em>, Colaris, Colaris AP, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:15%;width:15%;min-width:15%\">Media Contact:\u00a0<\/td>\n<td style=\"max-width:25%;width:25%;min-width:25%\">Jared Maxwell\u00a0<\/td>\n<td style=\"max-width:2%;width:2%;min-width:2%\">\u00a0<\/td>\n<td style=\"max-width:15%;width:15%;min-width:15%\">Investor Contact:\u00a0<\/td>\n<td style=\"max-width:43%;width:43%;min-width:43%\">Nathan Smith<\/td>\n<\/tr>\n<tr>\n<td>\u00a0<\/td>\n<td>(801) 505-5027<br \/><a href=\"mailto:jmaxwell@myriad.com\" rel=\"nofollow noopener\" target=\"_blank\">jmaxwell@myriad.com<\/a><\/td>\n<td>\u00a0<\/td>\n<td>\u00a0<\/td>\n<td>(801) 505-5067<br \/><a href=\"mailto:nathan.smith@myriad.com\" rel=\"nofollow noopener\" target=\"_blank\">nathan.smith@myriad.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/45672ffb-f7a8-4a7e-be92-ff0390427b0c\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) &#8212; On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash. About Myriad Genetics Myriad Genetics, is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-499825","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) &#8212; On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash. About Myriad Genetics Myriad Genetics, is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions &hellip; Continue reading &quot;Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-01T11:08:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences\",\"datePublished\":\"2021-06-01T11:08:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/\"},\"wordCount\":222,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/\",\"name\":\"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=\",\"datePublished\":\"2021-06-01T11:08:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/","og_locale":"en_US","og_type":"article","og_title":"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences - Market Newsdesk","og_description":"SALT LAKE CITY, June 01, 2021 (GLOBE NEWSWIRE) &#8212; On May 28, 2021, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, completed the sale of its wholly-owned subsidiary, Myriad myPath, LLC, which owns the laboratory that offers the myPath Melanoma test, to Castle Biosciences, Inc for $32.5 million in cash. About Myriad Genetics Myriad Genetics, is a leading genetic testing and precision medicine company dedicated to advancing health and wellbeing for all, empowering individuals with vital genetic insights and enabling healthcare providers to better detect, treat and prevent disease. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions &hellip; Continue reading \"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-01T11:08:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences","datePublished":"2021-06-01T11:08:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/"},"wordCount":222,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/","name":"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=","datePublished":"2021-06-01T11:08:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI0NjA5NiM0MjIwMTIxIzIwMDc4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-completes-the-sale-of-myriad-mypath-melanoma-llc-laboratory-to-castle-biosciences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myriad Genetics Completes the Sale of Myriad myPath\u00ae Melanoma, LLC, Laboratory to Castle Biosciences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499825","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=499825"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/499825\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=499825"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=499825"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=499825"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}